Article Per Year (5 Year)
p-Index From 2020 - 2025
0.408
P-Index
This Author published in this journals
All Journal MEDICINUS
Nicholas Adriel Pinzon
Unknown Affiliation
Biochemistry, Genetics & Molecular Biology Immunology & microbiology Medicine & Pharmacology Neuroscience Public Health

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

 1 
The Benefit of DLBS3233 as Add-on Therapy for Symptomatic Painful Diabetic Neuropathy: Case Series Rizaldy Taslim Pinzon; Abraham Al Jody; Nicholas Adriel Pinzon
MEDICINUS Vol. 38 No. 2 (2025): MEDICINUS
Publisher : PT Dexa Medica

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.56951/rhjkcb40

Abstract

Symmetrical painful diabetic neuropathy (PDN) is a highly prevalent form of diabetic peripheral neuropathy with significant morbidity. Despite its high prevalence, the optimal treatment of this condition remains a clinical challenge. There was an emergence need for add-on therapy that more focused on the dimensions of inflammation and toxic oxidative stress.Previous evidences from placebo-controlled studies have shown that opioids, antiepileptic, and antidepressant drugs are effective for alleviating PDN symptoms. In many cases, safety issues regarding potential side effects of those drugs limit the optimal use of the medications. We report case series of painful diabetic neuropathy in type 2 diabetic patients. DLBS3233 was given as add-on therapy to standard oral antidiabetic medication or insulin and adjuvant analgesics for all patients. After 3 months follow up, there was modest pain reduction and improvement in blood glucose control in allpatients. DLBS3233 was well tolerated in all patients. 
The Gastroprotective Effect of DLBS2411 for High-Risk Gastrointestinal Patients: Case Series in Inflammatory Pain Condition Rizaldy Taslim Pinzon; Abraham Al Jody; Nicholas Adriel Pinzon
MEDICINUS Vol. 38 No. 4 (2025): MEDICINUS
Publisher : PT Dexa Medica

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.56951/6197xj25

Abstract

Chronic pain is a common and distressing problem for the population. The cyclooxygenase (COX)-2 selective and nonselective nonsteroidal anti-inflammatory drugs (NSAIDs) are widely used in managing acute and chronic pain. Research has provided a greater understanding of the risks of gastrointestinal, cardiovascular, and renal events associated with NSAID use. Proton pump inhibitors (PPIs) are widely prescribed due to their gastroprotective effects in NSAID users. However, PPIs also have several acid-inhibition-related and unrelated adverse effects that limit their use in high-risk patients. We report five patients suffering from painful inflammatory pain (flare rheumatoid arthritis, painful knee bursitis, and osteoarthritis). In this case series we evaluate the use of DLBS2411 as an alternative to PPIs. Our study suggests that DLBS2411 can be a safe alternative to PPIs for gastrointestinal high-risk patients who require anti-inflammatory agents.
Co-Authors Abraham Al Jody Rizaldy Taslim Pinzon